These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20068094)

  • 41. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.
    Lin G; Gai R; Chen Z; Wang Y; Liao S; Dong R; Zhu H; Gu Y; He Q; Yang B
    Eur J Pharmacol; 2014 Apr; 729():45-53. PubMed ID: 24561043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
    Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
    Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M
    Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
    Civallero M; Cosenza M; Marcheselli L; Pozzi S; Sacchi S
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1597-606. PubMed ID: 22920938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells.
    Liu SL; Liu Z; Zhang LD; Zhu HQ; Guo JH; Zhao M; Wu YL; Liu F; Gao FH
    Cell Cycle; 2017; 16(24):2386-2395. PubMed ID: 28980866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
    Hu Y; Zhang K; Zhu X; Zheng X; Wang C; Niu X; Jiang T; Ji X; Zhao W; Pang L; Qi Y; Li F; Li L; Xu Z; Gu W; Zou H
    Int J Nanomedicine; 2021; 16():2173-2186. PubMed ID: 33758505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of combination treatment of the inhibitor of phosphatidyl inositol-3-kinase/protein kinase B pathway BEZ235 and the inhibitor of extracellular regulated protein kinase/mitogen-activated protein kinase pathway U0126 in a tumor cell model].
    Chen XX; Zhang S; Shi YZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Oct; 35(5):530-4. PubMed ID: 24183042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.
    Blatt K; Herrmann H; Mirkina I; Hadzijusufovic E; Peter B; Strommer S; Hoermann G; Mayerhofer M; Hoetzenecker K; Klepetko W; Ghanim V; Marth K; Füreder T; Wacheck V; Valenta R; Valent P
    PLoS One; 2012; 7(1):e29925. PubMed ID: 22299028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
    Hsu CM; Lin PM; Lin HC; Tsai YT; Tsai MS; Li SH; Wu CY; Yang YH; Lin SF; Yang MY
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30423811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.
    Pasello M; Manara MC; Michelacci F; Fanelli M; Hattinger CM; Nicoletti G; Landuzzi L; Lollini PL; Caccuri A; Picci P; Scotlandi K; Serra M
    Anal Cell Pathol (Amst); 2011; 34(3):131-45. PubMed ID: 21673434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
    Roper J; Richardson MP; Wang WV; Richard LG; Chen W; Coffee EM; Sinnamon MJ; Lee L; Chen PC; Bronson RT; Martin ES; Hung KE
    PLoS One; 2011; 6(9):e25132. PubMed ID: 21966435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
    Lin SF; Huang YY; Lin JD; Chou TC; Hsueh C; Wong RJ
    PLoS One; 2012; 7(10):e46726. PubMed ID: 23077520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation.
    Ruan B; Liu W; Chen P; Cui R; Li Y; Ji M; Hou P; Yang Q
    Int J Biol Sci; 2020; 16(4):682-693. PubMed ID: 32025215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells.
    Martin SK; Fitter S; Bong LF; Drew JJ; Gronthos S; Shepherd PR; Zannettino AC
    J Bone Miner Res; 2010 Oct; 25(10):2126-37. PubMed ID: 20499346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.